Search

Your search keyword '"Perry, W"' showing total 981 results

Search Constraints

Start Over You searched for: Author "Perry, W" Remove constraint Author: "Perry, W" Database Unpaywall Remove constraint Database: Unpaywall
981 results on '"Perry, W"'

Search Results

2. Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation

5. Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 Mpro Inhibitors

7. Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor

8. SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production

12. Supplementary Figure 2S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer

13. Supplementary Figure 1S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer

14. Supplementary Figure 4S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer

15. Supplementary Figure 3S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer

21. Discovery of 5′-Substituted 5-Fluoro-2′-deoxyuridine Monophosphate Analogs: A Novel Class of Thymidylate Synthase Inhibitors

22. SCCA1/SERPINB3 promotes suppressive immune environment via STAT-dependent chemokine production, blunting the therapy-induced T cell responses

23. Expanding the toolbox of metabolically stable lipid prodrug strategies

32. Curbing the Delta Surge

33. List of Contributors

35. Overall survival in patients with FIGO stage IVA cervical cancer

36. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography

42. Gestational Trophoblastic Neoplasms

43. Vagina

44. Corpus Uteri – Carcinoma and Carcinosarcoma

45. Vulva

46. Cervix Uteri

48. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Catalog

Books, media, physical & digital resources